samedan logo
 
 
spacer
home > ict > winter 2018 > perfect platform
PUBLICATIONS
International Clinical Trials

Perfect Platform

“Today, 47 million people live with dementia worldwide, more than the population of Spain. This number is projected to increase to more than 131 million by 2050, as populations age. Dementia also has a huge economic impact. The total estimated worldwide cost of dementia is US$818 billion, and it will become a trillion dollar disease by 2018” (1).

Because of the social impact of this chronic neurodegenerative disease, it has become a major target for new therapies and, together with Parkinson’s, accounts for approximately a third of all neurological trials initiated over the past five years (2). Despite this, the success of new medicines in the area is poor. At present, the only products on the market are Cholinesterase inhibitors and N-methyl-D-asparate (NMDA) antagonists, providing symptomatic therapy. Consequently, the drive for diseasemodifying treatments is huge, and, despite major setbacks for drugs in trials to date, in 2016, 51 Alzheimer’s trials were initiated compared to five in 2002 (3,4). Dominantly Inherited Alzheimer Network Trial (DIAN-TU) represents a new frontier for assessing the impact of disease-modifying drugs as it targets patients with a genetic predisposition and starts treatment prophylactically.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Graham Wylie has more than 25 years’ experience in the pharma industry working for Pfizer, PAREXEL, and Healthcare at Home. He was also named as one of the most influential leaders in the pharma industry by PharmaVOICE 100 in 2014. Graham joined Healthcare at Home in 2005 to set up their trial division and led the management buy out to create MRN in 2006.
spacer
Graham Wylie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG to Showcase its Range of Capsules and Engineering Solutions at Supply Side West, Las Vegas

ACG, the only supplier in the world offering end-to-end manufacturing solutions for the pharmaceutical and the nutraceutical industries, will be exhibiting its wide range of Engineering and Capsules solutions at this year’s Supply Side West, Las Vegas. At ACG’s booth, the visitors will be able to see the synergies created with coupling ACG’s Capsules and Engineering products, thereby leveraging the many benefits of integrated manufacturing.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

14th Annual Biomarkers Congress

21-22 February 2019, Manchester Central Convention Complex, UK

Oxford Global is proud to present for the 14th year our flagship Biomarkers Congress, taking place 21 – 22 February 2019 in Manchester, UK. An updated programme ensures you will benefit from talks on the latest strategies and technologies impacting growth in the biomarker industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement